US · BGM
BGM Group Ltd.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Chengdu 610200
- Website
- bgm.ltd
Price · as of 2024-09-30
$0.30
Market cap 222.69M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $42.39 | +13,983.06% |
| Intrinsic Value(DCF) | $5.45 | +1,710.63% |
| Graham-Dodd Method(GD) | $4.92 | +1,533.55% |
| Graham Formula(GF) | $7.16 | +2,279.4% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $4.31 | $93.17 | |||
| 2019 | $6.65 | $0.07 | |||
| 2020 | $7.34 | $11.83 | |||
| 2021 | $14.73 | $231.31 | $26.34 | $10.36 | $10.04 |
| 2022 | $5.34 | $222.47 | $92.12 | $8.09 | $3.15 |
| 2023 | $2.37 | $264.53 | $1.72 | $0.00 | $20.49 |
| 2024 | $8.49 | $42.39 | $3.23 | $4.92 | $7.16 |
AI valuation
Our deep-learning model estimates BGM Group Ltd.'s (BGM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $42.39
- Current price
- $0.30
- AI upside
- +13,983.06%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.45
+1,710.63% upside
Graham-Dodd
$4.92
+1,533.55% upside
Graham Formula
$7.16
+2,279.4% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BGM | BGM Group Ltd. | $0.30 | 222.69M | +13,983% | +1,711% | +1,534% | +2,279% | -40.44 | 1.44 | 2.44 | 49.11 | — | 1.61 | 16.39% | -2.25% | -5.75% | -3.55% | -1.76% | -2.91% | 0.00 | -0.88 | 3.39 | 2.73 | -11.16 | -8148.00% | -4599.00% | -43.00% | -5.52% | 0.06 | -14.87% | 0.00% | 0.00% | 4.76% | -76.65 | -12.76 | 1.72 | 5.16 |
| ANIP | ANI Pharmaceuticals, Inc. | $73.90 | 1.66B | +30% | +2,956% | -42% | +164% | 19.26 | 2.79 | 1.71 | 7.47 | — | -1176.59 | 0.00% | 12.58% | 8.87% | 16.16% | 12.26% | 5.75% | 0.60 | 5.54 | 2.71 | 2.04 | 0.19 | -41923.00% | 4378.00% | 29356.00% | 12.28% | 0.67 | 25.00% | 0.08% | 1.50% | 30.03% | 13.93 | 8.36 | 1.75 | 2.25 |
| AVDL | Avadel Pharmaceuticals pl… | $21.64 | 2.12B | +273% | +125% | — | — | -15.41 | 10.19 | 4.45 | -19.13 | — | 13.20 | 90.97% | -25.07% | -28.87% | -60.44% | -426.40% | -29.69% | 0.02 | -3.91 | 2.75 | 2.21 | 1.40 | -7450.00% | 50479.00% | -6350.00% | -6.23% | -0.96 | -474.12% | 0.00% | 0.00% | 7.16% | -16.05 | -14.51 | 4.02 | -0.97 |
| CLOV | Clover Health Investments… | $2.09 | 1.08B | +1,430% | +6,971% | — | — | -12.33 | 3.42 | 0.55 | -11.45 | -13.17 | 3.45 | 103.58% | -4.44% | -4.45% | -26.33% | -51.38% | -15.25% | 0.00 | — | 1.47 | 0.46 | 0.93 | 9362.00% | 4034.00% | -30721.00% | -6.54% | -0.32 | -41.43% | 0.00% | 0.00% | 0.10% | -11.22 | -13.92 | 0.50 | 0.06 |
| EWTX | Edgewise Therapeutics, In… | $30.44 | 3.22B | — | — | — | — | -18.22 | 5.85 | — | -13.38 | -146.76 | 5.85 | 0.00% | — | — | -34.19% | 3798.11% | -32.29% | 0.01 | — | 19.85 | 19.37 | 0.30 | 1241.00% | — | 3057.00% | -4.71% | -5.25 | 2858.86% | 0.00% | 0.00% | 0.66% | -13.22 | -17.57 | — | 59.04 |
| GPCR | Structure Therapeutics In… | $62.98 | 3.63B | — | — | — | — | -26.37 | 2.46 | — | -16.39 | -1028.46 | 2.46 | 0.00% | — | — | -11.86% | -570.89% | -11.35% | 0.00 | — | 24.81 | 22.85 | 5.69 | 256.00% | — | 9149.00% | -6.06% | -3.51 | -730.15% | 0.00% | 0.00% | 16.85% | -12.94 | -10.11 | — | 33.44 |
| MESO | Mesoblast Limited | $15.85 | 2.04B | +203% | -57% | — | — | -17.02 | 2.91 | 101.06 | -23.15 | — | 67.85 | 70.17% | -363.08% | -593.92% | -18.95% | -11.34% | -14.05% | 0.21 | -2.72 | 1.99 | 1.72 | 0.45 | -562.00% | 19139.00% | 388.00% | -2.92% | -0.49 | -9.21% | 0.00% | 0.00% | 5.14% | -27.31 | -33.64 | 99.14 | 3.68 |
| PAHC | Phibro Animal Health Corp… | $54.59 | 2.21B | +18% | +113% | -92% | -25% | 32.91 | 5.56 | 1.23 | 15.48 | 1.75 | 8.38 | 30.85% | 8.52% | 3.72% | 17.80% | 9.58% | 4.12% | 2.67 | 3.32 | 2.76 | 1.04 | 4.72 | 188333.00% | 2737.00% | -976.00% | 2.63% | 0.27 | 5.11% | 1.22% | 40.30% | 1.22% | 20.57 | 54.33 | 1.75 | 2.84 |
| PRCT | PROCEPT BioRobotics Corpo… | $22.69 | 1.27B | +83% | +106% | — | — | -15.10 | 3.94 | 4.69 | -15.09 | — | 3.95 | 63.70% | -33.71% | -31.02% | -24.89% | -74.26% | -18.34% | 0.14 | -11.69 | 6.85 | 5.62 | 2.93 | -171.00% | 3722.00% | -4370.00% | -4.04% | -0.74 | -41.71% | 0.00% | 0.00% | 0.44% | -11.64 | -20.71 | 3.92 | 5.16 |
| QDEL | QuidelOrtho Corporation | $22.74 | 1.54B | -6% | -60% | — | — | -1.35 | 0.80 | 0.56 | -8.47 | — | -2.38 | 46.67% | -33.67% | -41.45% | -46.15% | -18.22% | -18.56% | 1.46 | -5.18 | 1.50 | 0.64 | -5.40 | -4535.00% | -189.00% | -2596.00% | -5.42% | 0.11 | -1.65% | 0.00% | 0.00% | 0.00% | -4.50 | -49.82 | 1.51 | 0.29 |
| TWST | Twist Bioscience Corporat… | $46.92 | 2.88B | -25% | -66% | -100% | — | -24.87 | 4.08 | 5.13 | -35.25 | — | 5.12 | 50.72% | -36.18% | -20.63% | -16.43% | -41.34% | -12.37% | 0.29 | — | 3.64 | 3.17 | 0.88 | -6389.00% | 2032.00% | 934.00% | -3.92% | -0.52 | -22.95% | 0.00% | 0.00% | 0.00% | -13.48 | -24.28 | 4.88 | 4.32 |
About BGM Group Ltd.
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
- CEO
- Chen Xin
- Employees
- 298
- Beta
- 1.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.45 ÷ $0.30) − 1 = +1,710.63% (DCF, example).